Illumina (ILMN) said Tuesday that it will be reimbursed $2,989.55 by the Centers for Medicare and Medicaid Services for each of its TruSight genomic profiling tests.

The company said the reimbursement became effective Jan. 1.

Illumina said its TruSight Oncology Comprehensive test is approved as a companion diagnostic to identify patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions, and who may benefit from Bayer's cancer drug VITRAKVI.

Price: 141.67, Change: +0.01, Percent Change: +0.01